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Tyrosine phosphorylation is a key controlling mechanism in signal transduction 
and enzyme activity regulation. Dysfunction of Fyn kinase, a unique member 
of non-receptor Src kinase family is implicated in oncogenesis, T-cell mediated 
diseases and neuronal disorders. Fyn kinase has been recognized as an 
important target for anti-cancer therapeutics. An insilico virtual screening of 
open and closed states of Fyn with seventy phytochemicals used in cancer 
treatment was carried out.  Molecular properties and bioactive spectrum 
analysis further improved the screening process by forming a data set 
containing seven potential hits. Ligand efficiency score which combines 
biological and chemical space together identified three secondary metabolites 
apigenin, genistein and quercetin as efficient inhibitors of Fyn kinase.  A 
reverse virtual screening approach validated the target selection by identifying 
Src kinase family members as potential drug targets. Drug-target interaction 
network based on feature scores of 22 phytochemicals which survived the 
initial screening process further validated our findings.  A conceptual 
optimization may be required to reduce attrition and increase the activity of the 
lead.  
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1. INTRODUCTION  
Tyrosine kinases (TK) are crucial mediators in several signaling cascades acting as molecular switches [1]. 
Tyrosine kinase signaling pathways normally prevent deregulated proliferation or contribute to sensitivity 
towards apoptotic stimuli. These signaling pathways are often genetically or epigenetically altered in cancer cells 
to impart a selection advantage to the cancer cells [2].  
The dysregulation of TKs occur in many different ways in cancer cells. The first mechanism is by fusion of 
TKs with a partner protein, a consequence of chromosomal translocation. Second mechanism of impairment is 
by mutations degrading the kinase auto-regulation process. Other mechanisms include over-expression of their 
ligands and decrease in factors that limit their activity. All these aberrant actions may lead to increase 
angiogenesis, invasiveness and drug resistance in malignant cells [1]. Two major classes of TKs have been 
reported [3]. Receptor tyrosine kinases (EC 2.7.10.1) are transmembrane proteins with ligand-binding domain 
and catalytic domain. The catalytic activity is triggered by ligand binding, after which the receptor oligomerizes, 
breaks the cytoplasmic juxtamembrane interactions and autophosphorylates a regulatory tyrosine residue within 
the kinase activation domain. Upon activation, auto-phosphorylation generates binding sites for signaling 
proteins, recruiting them to the membrane and activating multiple signaling cascades. Similarly non-receptor 
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kinases (NTKs) (EC 2.7.10.2) upon activation, cleaves the signal inhibitors, oligomerizes and 
autophosphorylates a regulating tyrosine residue leading to signal transduction. In humans, about 20 families of 
receptor tyrosine kinases and 10 families of non- receptor tyrosine kinases have been reported [4]. 
Fyn is a member of the nonreceptor Src-family tyrosine kinases. Other members of Src-kinase family 
include Lck, Src, Yes, Lyn, Hck, Blk, Fgr and Yrk tyrosine kinase [5]. Fyn kinase actively participates in T-cell 
signal transduction. It is activated by the stimulation of T-cell antigen receptors.  ITAM sequences 
(immunoreceptor tyrosine activation motif) of the CD3 subunit and ζ-chain of T-cell receptors are then 
phosphorylated by Fyn. This is the prerequisite step for ZAP-70 kinase binding to ITAM and phosphorylation of 
LAT18 and SLP-76 adaptor proteins that enable further downstream signaling pathways. This signaling process 
results in the proliferation and differentiation of T-cells. Fyn resides in specialized plasma membrane micro 
domains, termed as lipid rafts. Genetic evidence demonstrates that Fyn activation is strictly connected with T-
cell receptor-induced translocation of Lck. Activated Fyn plays a critical role in skin cancer development. In 
keratinocyte cell-cell adhesion Rho/PKR2 signaling, Fyn is reported as a downstream mediator [4].  
Crystallographic and biochemical studies reveal that kinase activity is regulated through reversible 
phosphorylation of two key tyrosine residues. In closed conformation Fyn kinase remains inactive by two week 
intra-molecular interactions formed between SH2 domain and phosphorylated C-terminal tyrosine (TYR531) and 
SH3 domain and the linker region. Dephosphorylation of the C-terminal tyrosine mediated by CD45 results in 
open conformation. The catalytic activity is conferred by phosphorylation of regulatory tyrosine (TYR420) in the 
activation loop [6]. 
Our study aims at identifying inhibitors of plant origin against Fyn kinase by reverse virtual screening 
approach. Insilico docking based virtual screening aids the discovery of potent hits. Lipinski filter and bioactive 
spectrum predictions are employed to identify more potent leads. A Drug-target network is constructed to 
identify compounds interacting with common partners. A more stringent screening strategy adopted by 
employing ligand efficiency score identified the final potential lead compounds. 
 
 
2. RESEARCH METHOD  
2.1 Non receptor kinase Fyn as a therapeutic target  
 Discovery of small molecular drug candidates typically begins with the identification and validation of 
the target. In this study we consider Fyn kinase as a potential target because of its greater impact in mediating 
diseases such as cancer, allergy and Alzheimer’s. Fyn is a proto-oncogene tyrosine-protein kinase (p59fyn) 
classified as a phosphotransferase. Fyn kinase sequence was retrieved from UniProt database (UniProt ID: 
P06241). Closed and open structures of Fyn kinase were modeled by homology modeling using modeller 9.7 [7]. 
In order to identify homologous sequences with known 3D structures, a protein-protein BLAST was performed 
against protein data bank (PDB) [8]. Models were built with phosphorylated side chains using 1Y57, 2DQ7 and 
2H8H as templates. Table 1 represents the detailed information ranging from template identification to model 
validation. The backbone dihedral angle distributions of all amino acids were verified using Procheck 
Ramachandran plot [9]. The fold quality was inspected by ProSA web server [10] and the predicted model 
quality was verified by QMEAN score [11].  
 
Table 1. Template and structure validation statistics for the modeled protein 
 
1
Percentage of residues in most favored region, 
2
 Percentage of residues in additionally allowed region, 
3
Percentage of residues in generously allowed region, 
4
Percentage of residues in disallowed region, 
5
Overall 
model quality and 
6
Model quality estimation.  
 
 
 
Protein Template 
PDB ID 
Query coverage 
(%) 
Identity 
(%) 
Procheck ProSA 
Z 
score
5 
QMEAN 
score
6 
A
1
 B
2
 C
3
 D
4
 
Fyn open 
1Y57 99 77 
91.6 -7.11 6.1 1.5 -9.77 0.736 
2DQ7 61 99 
Fyn 
Close 
2H8H 99 77 92.3 5.9 1.3 0.5 -10.07 0.749 
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2.2 Identification of bioactive compounds  
Phytocompounds offer wide scope of cure for many inherent diseases. The high-throughput experimental 
findings of anti-cancer bioactive compounds were manually curated from three different databases: PubChem 
[12], DIACAN [13] and cancer plants database (http://cancerplantsdatabase.com). The selection of 
phytochemicals of our work is restricted to compounds whose activity has been proved against various cancer 
cell lines. To give an emphasis on Indian medicinal plants, seventy compounds of Indian origin were selected for 
the study. The structures of all the compounds were retrieved from PubChem database. S.Table. 1 presents the 
source of phytochemical compounds of our work.  
2.3 Virtual screening  
Virtual screening offers computational prediction of binding affinity for diverse set of compounds [14]. A 
high throughput docking study was carried out using AutoDock Vina tool [15]. AutoDock 4.2 [16] was used to 
prepare the initial files. Hydrogen atoms were added, non-polar contacts were merged and Gastegier charges 
were computed for the proteins. Open and closed conformations of Fyn were processed separately. The ligand 
files were prepared using AutoDock Raccoon tool [17]. The search space of was set for the protein allowing the 
ligands to choose their preferential binding site.  
2.4 Rule of five and bioactive spectrum prediction  
Lipinski rule of five (RO5) aids in identifying chemical entities with favorable physiochemical properties. 
The compounds were subjected to RO5 analysis using MolInspiration server (http://www.molinspiration.com). 
Bioactive spectrum of the compounds determines their potential roles based on their signature pharmacophore. 
The probable activity score towards kinase inhibition was calculated using PASS server [18].  
2.5 Network Building  
Network analysis interprets the complex relationship existing between the drug and the target. The drug-
target network was established by connecting the potential compounds and their potential target. PharmMapper 
server [19] employs principles of Pharmacophore mapping to spot potential molecular target candidates for a 
known small bioactive molecule. The database was searched for human targets with a threshold of 1000 hits. The 
final list was scrutinized to obtain only NTKs from the predicted results using Perl script. A drug – target 
network was constructed and visualized using Cytoscape 2.7 [20]. In the graphic network, molecular species 
(compounds and proteins) are represented as nodes and inter-molecular connections (drug-target) are indicated 
as edges between the nodes. 
 
3. RESULTS AND ANALYSIS  
3.1 Fyn in open and closed conformations – Structural and functional uniqueness  
The three-dimensional structure of Fyn tyrosine kinase has not been reported previously, with the exception 
of few crystal structures of Fyn SH3 or SH2 domains. Human Fyn kinase contains 537 amino acids. It has a 
unique structure comprising an N-terminal region anchoring to the membrane, SH4 domain, SH3 and SH2 
domains mediating interactions with protein partners, SH1 kinase domain and a C-terminal tail involved in 
negative regulatory function [21]. The functional uniqueness is maintained by acting as a molecular switch 
turning itself on and off through phosphorylation of either Tyr420 or Tyr531 residue. The phosphorylation status 
of Tyr531 in the C-terminal tail determines the open and closed conformation of Fyn. In closed state Tyr531 is 
phosphorylated and conversely unphosphorylation keeps Fyn in open state and it can be activated by 
phosphorylation at Tyr420. The open state of Fyn forms the basis for kinase activity. Hence Fyn open structure 
with phosphorylated Tyr420 and closed structure with phosphorylated Tyr531 have been modeled.  
3.2 Model building and validation 
The BLASTP search identified several homologous sequences with known 3D protein structures. Based on 
the query coverage and sequence identity, 2 templates for open conformation of Fyn (PDB ID: 1Y57, 2DQ7) and 
a single template (PDB ID: 2H8H) for closed conformation were chosen. In open state Tyr420 and in closed 
state Tyr531 were phosphorylated. The SH3 Kinase domain and C-terminal tail plays a major role in the enzyme 
activation and hence the first 85 residues corresponding to N terminus region were excluded from model 
building (Figure. 1). The secondary structural profile and accessibility were estimated by Ramachandran plot 
using Procheck server. The open conformation has 95.5% of residues in the allowed region and the closed 
conformation has 99.2% of in the allowed region. This shows that the models generated have good 
stereochemical features. The fold quality assessed by ProSA web server produced a Z score of -9.77 for open 
and -10.07 for close conformation validating the model produced. The QMEAN score of the closed and open 
Fyn models are 0.75 and 0.737 as predicted by the Swissmodel server. The QMEAN computes a composite 
scoring from global (i.e. for the entire structure) and local (i.e. per residue) error estimates on the basis of a 
single model. The QMEAN score falls within the interval of 0 to 1 and hence the high accuracy of the models is 
proven.  
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Figure. 1 Fyn kinase modeled structures and their Z-score plots (a) Cartoon representation of Fyn kinase in 
close state with phosphorylated Tyr531 shown as sticks (b) Cartoon representation of Fyn kinase in open state 
with phosphorylated Tyr420 shown as sticks (c) Z-score plot of Fyn closed conformation (d) Z-Score plot of Fyn 
open conformation. The circle indicates the position of predicted model. 
3.3 Hit identification - Virtual screening, physiochemical properties and bioactive spectrum filters  
Hit identification ideally results in set of compounds that interact with the target. We have applied high 
throughput virtual screening method to identify compounds with favorable binding affinity towards open and 
closed conformation of Fyn kinase. The ligands with high binding energy ranging from -10 to -8 Kcal/mol were 
selected for next step of processing. 35 compounds for open conformation and 25 compounds for closed 
conformation were selected based on their binding energy values. 22 compounds which showed high preference 
in both close and open states formed the dataset for next step of screening process. 
The physiochemical properties identify compounds which have futuristic lead like potential [22]. 
Optimizing the binding potency of a ligand independent of the size of the ligand to improve large scale screening 
experiments is of adverse need. One such measure is ligand efficiency (LE) [23] which is calculated using the 
formula described in equation (1).  
LE = affinity /N ------- (1) 
 
The affinity corresponds to compounds binding energy and N is the number of non-hydrogen atoms. 
Molecular weight of the compounds plays a major governing role in ligand efficiency. Further to the extension 
of screening strategy kinase inhibition scores predicted by PASS server eliminated compounds with minimum (< 
0.4) kinase inhibitory scores. Table 2 presents the parameter scores of aloe-Emodin, apigenin, brazilin, daidzein, 
genistein, rhein and quercetin identified as fruitful hits from the above screening process.  
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Table 2 Physiochemical properties, biospectrum and ligand efficiency scores of final seven compounds 
Sl.No Phytochemicals milogP Molecular 
Weight 
nON
1 
nOHNH
2 
Kinase 
inhibition 
P
a 
score
3
 
Ligand 
efficiency 
1.  Aloe-Emodin 2.424 270.24 5 3 0.441 -0.46 
2.  Apigenin 2.463 270.24 5 3 0.941 -0.45 
3.  Brazilin 1.285 286.283 5 4 0.507 -0.42 
4.  Daidzein 2.559 254.241 4 2 0.722 -0.47 
5.  Genistein 2.268 270.24 5 3 0.844 -0.45 
6.  Quercetin 1.683 302.238 7 5 0.957 -0.4 
7.  Rhein 2.997 284.223 6 3 0.468 -0.41 
1
Hydrogen bond acceptor, 
2
Hydrogen bond donor, 
3
Probability to be active 
 
3.4 Lead identification  
Biological activity spectrum reflects the interaction of chemical entity with biological entity. The predicted 
Pa falling above 0.7 indicates high probability of the substance being analogue of a known pharmaceutical agent. 
The compounds apigenin (Pa - 0.941), genistein (Pa - 0.844) and quercetin (Pa - 0.957) were observed to show 
greater predicted kinase inhibition activity. Size related efficiency indices are currently used for selecting leads 
for fragment based drug designing. Ligand Efficiency of -0.40 was set as minimum gain for the compounds to 
evolve from ‘lead-like’ to ‘drug-like’. The ligand efficiency score for apigenin (-0.45), genistein (-0.45) and 
quercetin (-0.40) were observed to fall above the desired range. Figure. 2 depicts a distribution plot of key 
properties playing a major role in lead identification.  
 
Figure. 2 Screening parameter values of final seven hits. (Molecular weight is scaled by multiplying 10
2
). 
3.5 Lead validation – A networks approach  
The study further validated the reliability of the candidate target and compounds using network approach. 
A detailed analysis about the connections between the compounds and targets were carried out using network 
pharmacology approach. The drug-target network [24] computed based on fit score and matching 
pharmacophore features validated the above results. Successors of initial screening process were reported to 
interact with many members of NTKs. Upon close observation of the final network revels that apigenin, 
genistein and quercetin interact with all the members of SRC kinase family. By homology we confirm that these 
compounds can act as potential inhibitors of Fyn kinase. Figure. 3 portrays the drug-target network of 22 
compounds identified from initial screening and also their interaction with NTKs. 
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Figure. 3 Drug- Target Networks predicted using Cytoscape 2.7 (a) Drug target network of proteins with 22 
compounds. Red circles indicate the proteins and green circles indicate the compounds. (b) Interaction network 
of NTKs with the initial survivors. (c) Interaction network of final seven hits with NTKs. (see S.Table 2 for 
compound names). 
  
3.6 Binding mode analysis of lead compounds  
Several groups reported the crystal structure of SH3 and SH2 domain of Fyn kinase. Based on their 
observation an ATP binding domain is observed opposite to SH2 and SH3 domains. A 28 residue long 
(408∙∙∙∙436) segment forms an activation center of Fyn kinase domain. Asp408 residue chelates magnesium ion 
and positions the phosphate for phosphor-transfer. An ATP binding site (280∙∙∙∙420) is also included in this 
activation loop.  Signature residues like Glu343, Met345 and Asp408 which were reported to show interaction 
with the drug staurosporine and ADP (Dubravko Jelic et al., 2007) were also observed to interact with our top 
three leads. The final successful leads interact with residues in kinase activation loop thereby promising efficient 
inhibition. The target-ligand interaction details are summarized in Table 3.  
 
Table 3 Binding energy and interacting residues of top three lead compounds 
Phytochemical Binding Energy 
Kcal/mol 
Interacting residues in open 
conformation 
Interacting residues in closed 
conformation 
Open 
state 
Close 
state 
Apigenin -9.2 -8.6 Lys299, Glu343, Met345 Lys295, Tyr330, Asn400, 
Lys405 (+-п) 
Quercetin -9.0 -8.0 Glu314, Thr342(σ-п), Tyr344(п-п), 
Met345, Asp408 
Tyr330, Glu343, Asn400 
Genistein -8.9 -8.5 Lys299,Tyr344(п-п), 
Met345,Asp408 
Lys299, Thr330, Arg392, 
Asp408 
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The binding groove and interaction pattern of apigenin with Fyn kinase is illustrated in Figure. 4. 
 
Figure. 4 Binding pose of Fyn kinase with apigenin in open and close state (a) The open state Fyn is represented 
as surface and the bound apigenin is represented as ball and sticks. The crucial binding site residues are coloured 
green. Binding of apigenin represented in ball and stick with open Fyn represented in surface. The binding site 
residues are coloured green. (b) 2D ligand plot showing the bonding patterns and interacting residues of apigenin 
with open Fyn. (c) The closed state Fyn is represented as surface and the bound apigenin is represented as ball 
and sticks. The crucial binding site residues are coloured green. Binding of apigenin represented in ball and stick 
with open Fyn represented in surface. The binding site residues are coloured green. (d) 2D ligand plot depicting 
interacting residues of closed Fyn with apigenin. The green and blue arrows represent hydrogen bondings and 
the orange line indicates ca-pi interaction.  
 
4. CONCLUSION  
The current analysis provides a brief scenario of Fyn kinase structure and function. The virtual screening process 
in search of potential leads against Fyn kinase identified compounds of high potency. The filters such as 
physiochemical properties, bio-active spectrum and ligand efficiency provided a numerical framework 
combining the potency towards the biological space (target) and chemical space (ligands). These numerical 
systems will facilitate drug discovery process by minimizing the cost and time to narrow down more potent and 
efficient leads.  
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